Research programme: somatostatin receptor agonists - Juvantia Pharma

Drug Profile

Research programme: somatostatin receptor agonists - Juvantia Pharma

Alternative Names: Somatostatin receptor agonists research programme - Juvantia Pharma

Latest Information Update: 18 Feb 2009

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Juvantia Pharma
  • Class
  • Mechanism of Action Somatostatin receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • No development reported Benign prostatic hyperplasia; Coronary artery restenosis; Eye-Disorders; Pain; Prostate cancer; Skin disorders; Vascular restenosis

Most Recent Events

  • 25 Jun 2005 Preclinical trials in Benign prostatic hyperplasia in Finland (unspecified route)
  • 25 Jun 2005 Preclinical trials in Pain in Finland (unspecified route)
  • 30 May 2005 This programme is still in active development
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top